PMV Pharmaceuticals, Inc.

# Signal Note: OrbiMed Initiates $6.2M Position in PMV Pharmaceuticals OrbiMed's new 4.98M-share stake in PMVP signals conviction in the company's lead asset, PC786, a selective p53 reactivator in development for TP53 wild-type cancers (notably ovarian and endometrial). The timing likely reflects confidence in near-term clinical catalysts, as PC786 has shown preliminary efficacy signals warranting continued investment despite PMVP's modest market cap and capital requirements. OrbiMed's entry provides validation from a tier-1 investor with deep oncology expertise, though investors should monitor clinical readouts and cash runway closely.